Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA reform requires cultural change, not new legislation, Allergan's Herbert suggests.

This article was originally published in The Gray Sheet

Executive Summary

CONGRESSIONAL PRESSURE, RATHER THAN LEGISLATION, IS BEST ROUTE TO FDA REFORM, Allergan Chairman Gavin Herbert suggested at a May 2 Capitol Hill briefing sponsored by the California Health Care Institute (CHI). "Frankly, I am not sure we need a new law," Herbert said. "What we need is...perhaps some feet held to the fire by various congressional staffs to cause the agency to act in a more responsible way."

You may also be interested in...



EU Preserves Status Quo On Drugs Under Additional Monitoring

The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.

Meitheal Gets US Enoxaparin Approval

Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.

EU Approvals: Evenity Cleared For Severe Osteoporosis

The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.

 

UsernamePublicRestriction

Register

MT004045

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel